Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$85.21M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
1744.27%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$288.4M
Q3 2024
Cash
Q3 2024
P/E
-13.59
Nov 29, 2024 EST
Free Cash Flow
-$68.53M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017
Selling, General & Admin $18.96M $15.33M $13.00M $9.540M $5.110M $2.440M $990.0K
YoY Change 23.65% 17.92% 36.27% 86.69% 109.43% 146.46%
% of Gross Profit
Research & Development $64.57M $18.94M $38.44M $32.15M $19.01M $8.240M $7.920M
YoY Change 240.94% -50.73% 19.56% 69.15% 130.69% 4.04%
% of Gross Profit
Depreciation & Amortization $297.0K $600.0K $100.0K $100.0K $33.00K $0.00
YoY Change -50.5% 500.0% 0.0% 203.03%
% of Gross Profit
Operating Expenses $83.53M $34.27M $51.44M $41.70M $24.12M $10.68M $8.910M
YoY Change 143.74% -33.38% 23.37% 72.91% 125.81% 19.87%
Operating Profit -$83.53M $730.0K -$51.44M -$41.70M -$24.12M
YoY Change -11542.33% -101.42% 23.37% 72.91%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017
Interest Expense $11.97M $943.0K $233.0K $483.0K $578.0K $0.00 $0.00
YoY Change 1169.03% 304.72% -51.76% -16.44%
% of Operating Profit 129.18%
Other Income/Expense, Net -$22.00K $846.0K $58.00K $338.0K $653.0K -$660.0K $9.130M
YoY Change -102.6% 1358.62% -82.84% -48.24% -198.94% -107.23%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017
Pretax Income -$71.58M $1.576M -$51.38M -$41.36M -$23.46M -$11.34M $220.0K
YoY Change -4642.13% -103.07% 24.24% 76.3% 106.88% -5254.55%
Income Tax $0.00 $88.00K $0.00
% Of Pretax Income 5.58% 0.0%
Net Earnings -$71.58M $1.488M -$51.38M -$41.36M -$23.46M -$11.34M $220.0K
YoY Change -4910.75% -102.9% 24.24% 76.28% 106.9% -5254.55%
Net Earnings / Revenue
Basic Earnings Per Share -$2.01 $0.06 -$2.37
Diluted Earnings Per Share -$2.01 $0.06 -$2.372M -$2.971M -$1.415M -$684.0K $13.27K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017
Cash & Short-Term Investments $253.1M $75.54M $90.28M $88.22M $28.91M $7.380M $9.670M
YoY Change 235.12% -16.33% 2.33% 205.15% 291.73% -23.68%
Cash & Equivalents $100.1M $75.54M $48.31M $47.70M $4.940M $7.380M $9.670M
Short-Term Investments $153.0M $41.97M $40.52M $23.97M $0.00
Other Short-Term Assets $13.00M $2.220M $2.418M $2.180M $1.720M $320.0K $550.0K
YoY Change 485.72% -8.19% 10.92% 26.74% 437.5% -41.82%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $266.2M $77.75M $92.70M $90.41M $30.62M $7.710M $10.22M
YoY Change 242.32% -16.12% 2.53% 195.26% 297.15% -24.56%
Property, Plant & Equipment $1.062M $1.520M $775.0K $350.0K $440.0K $0.00 $0.00
YoY Change -30.13% 96.13% 121.43% -20.45%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.654M $4.030M $175.0K $90.00K $2.230M $0.00 $0.00
YoY Change 15.48% 2202.86% 94.44% -95.96%
Total Long-Term Assets $5.716M $5.550M $950.0K $430.0K $2.680M $0.00 $0.00
YoY Change 2.99% 484.21% 120.93% -83.96%
Total Assets $271.9M $83.30M $93.65M $90.84M $33.30M $7.710M $10.22M
YoY Change
Accounts Payable $532.0K $3.120M $2.360M $1.970M $1.660M $910.0K $430.0K
YoY Change -82.95% 32.2% 19.8% 18.67% 82.42% 111.63%
Accrued Expenses $15.36M $6.600M $4.850M $4.280M $2.540M $920.0K $400.0K
YoY Change 132.76% 36.08% 13.32% 68.5% 176.09% 130.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $25.89M $9.720M $7.210M $6.250M $4.200M $1.830M $830.0K
YoY Change 166.4% 34.81% 15.36% 48.81% 129.51% 120.48%
Long-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $660.0K
YoY Change -100.0%
Other Long-Term Liabilities $67.00K $660.0K $406.0K $160.0K $180.0K $0.00 $0.00
YoY Change -89.85% 62.56% 153.75% -11.11%
Total Long-Term Liabilities $67.00K $660.0K $406.0K $160.0K $180.0K $0.00 $660.0K
YoY Change -89.85% 62.56% 153.75% -11.11% -100.0%
Total Liabilities $25.96M $10.37M $7.616M $6.410M $4.380M $1.830M $1.490M
YoY Change 150.35% 36.16% 18.81% 46.35% 139.34% 22.82%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017
Basic Shares Outstanding 35.55M 26.29M 21.66M
Diluted Shares Outstanding 35.55M 26.39M 21.66M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $1.1585 Billion

About Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. The company is headquartered in Boulder, Colorado and currently employs 57 full-time employees. The company went IPO on 2020-03-12. The company is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. Its second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations. ELVN-002 is designed to inhibit wild type HER2 and key mutations of HER2, while sparing wild-type EGFR and avoiding EGFR-related toxicities.

Industry: Pharmaceutical Preparations Peers: 9 METERS BIOPHARMA, INC. Aquestive Therapeutics, Inc. NRX Pharmaceuticals, Inc. Eton Pharmaceuticals, Inc. JOHNSON & JOHNSON OPIANT PHARMACEUTICALS, INC. Medicine Man Technologies, Inc. Mystic Holdings Inc./NV Odonate Therapeutics, Inc.